Pfizer Takes Stake in Rhythm Pharmaceuticals Appetite, Bardet-Biedl Syndrome (BBS), Bardet-Biedl Syndrome (BBS), Biological Pathways, Business, Diabetic Gastroparesis, Equity Stake, Genetic Disorders, Ghrelin Agonists, Melanocortin-4 Receptor (MC4R) Agonists, Monogenic Disorders, Obesity, Pro-Opiomelanocortin (POMC) Deficiency Obesity, Product Pipelines, Rare Diseases, Stock Markets, U.S. Securities and Exchange Commission (SEC) Pfizer snapped up a small percentage of Rhythm Pharmaceuticals, which is focused on treating rare genetic disorders that lead to obesity. Read more October 19, 2017/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2017-10-19 12:44:062017-10-19 13:12:50Pfizer Takes Stake in Rhythm Pharmaceuticals
